| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Fortress Biotech Inc (NASDAQ: FBIO)
FBIO Technical Analysis
5
| As on 9th Jun 2023 FBIO STOCK Price closed @ 0.59 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.24 & Strong Sell for SHORT-TERM with Stoploss of 2.07 we also expect STOCK to react on Following IMPORTANT LEVELS. |
FBIOSTOCK Price
| Open | 0.59 | Change | Price | % |
| High | 0.60 | 1 Day | 0.01 | 1.72 |
| Low | 0.57 | 1 Week | 0.05 | 9.26 |
| Close | 0.59 | 1 Month | -0.15 | -20.27 |
| Volume | 413200 | 1 Year | -2.06 | -77.74 |
| 52 Week High 2.75 | 52 Week Low 0.48 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| FBIO Daily Charts |
FBIO Intraday Charts |
Whats New @ Bazaartrend |
FBIO Free Analysis |
|
|
FBIO Important Levels Intraday
| RESISTANCE | 0.65 |
| RESISTANCE | 0.63 |
| RESISTANCE | 0.62 |
| RESISTANCE | 0.61 |
| SUPPORT | 0.57 |
| SUPPORT | 0.56 |
| SUPPORT | 0.55 |
| SUPPORT | 0.53 |
FBIO Forecast May 2024
| 4th UP Forecast | 1.88 |
| 3rd UP Forecast | 1.47 |
| 2nd UP Forecast | 1.21 |
| 1st UP Forecast | 0.96 |
| 1st DOWN Forecast | 0.22 |
| 2nd DOWN Forecast | -0.03 |
| 3rd DOWN Forecast | -0.29 |
| 4th DOWN Forecast | -0.7 |
FBIO Weekly Forecast
| 4th UP Forecast | 1.40 |
| 3rd UP Forecast | 1.14 |
| 2nd UP Forecast | 0.98 |
| 1st UP Forecast | 0.82 |
| 1st DOWN Forecast | 0.36 |
| 2nd DOWN Forecast | 0.20 |
| 3rd DOWN Forecast | 0.04 |
| 4th DOWN Forecast | -0.22 |
FBIO Forecast2024
| 4th UP Forecast | 5.02 |
| 3rd UP Forecast | 3.6 |
| 2nd UP Forecast | 2.72 |
| 1st UP Forecast | 1.84 |
| 1st DOWN Forecast | -0.66 |
| 2nd DOWN Forecast | -1.54 |
| 3rd DOWN Forecast | -2.42 |
| 4th DOWN Forecast | -3.84 |
Fortress Biotech Inc ( NASDAQ USA Symbol : FBIO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
FBIO Business Profile
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York. Address: 2 Gansevoort Street, New York, NY, United States, 10014
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service